Viridian Therapeutics (VRDN) Proxy filing summary

Executive summary

• The annual meeting is scheduled for June 2, 2026, with voting on director elections, auditor ratification, executive compensation, and frequency of say-on-pay votes.

• The company achieved significant milestones in 2025, including a BLA submission and acceptance for veligrotug, completion of key clinical trials, and strong financial positioning with $875 million in cash and investments at year-end.

• The board recommends voting for the nominated directors, auditor ratification, executive compensation, and annual say-on-pay votes.

Voting matters and shareholder proposals

• Proposals include electing two Class II directors, ratifying KPMG LLP as auditor, approving executive compensation, and determining the frequency of say-on-pay votes.

• The board recommends voting for all proposals and for annual say-on-pay votes.

• Shareholders may submit proposals for the 2027 meeting by December 18, 2026.

Board of directors and corporate governance

• The board consists of seven members divided into three classes with staggered terms.

• All directors except the CEO are independent under Nasdaq rules.

• The board has Audit, Compensation, Nominating, and Science Committees, all composed of independent directors.

• The board encourages diversity, regular self-evaluation, and compliance with overboarding policies.